Syntara Prepares to Unveil Promising Myelofibrosis Data

Pharmaxis Ltd (AU:SNT) has released an update.

Syntara Limited is preparing to share interim data from its Phase 2 study of SNT-5505 for the treatment of myelofibrosis during a webinar, coinciding with its presentation at the American Society of Hematology meeting. The company, which specializes in drug development targeting extracellular matrix dysfunction, has already received FDA Orphan Drug Designation for SNT-5505 and is advancing its clinical trials. Investors and interested parties are encouraged to attend the webinar to gain insights into the promising developments in Syntara’s pipeline.

For further insights into AU:SNT stock, check out TipRanks’ Stock Analysis page.